|
Mechanisms of Tumor Escape and Metastatic Development in Mouse Models of Experime
|
Z01 SC 010371
|
$191,496
|
$19,150
|
Abrams, Scott
|
CCR (NCI)
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-04
|
$234,166
|
$23,417
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-11
|
$1,181,405
|
$590,703
|
Albelda, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Santa Rosa Memorial Hospital Regional CCOP
|
3U10CA063850-12S2
|
$131,400
|
$1,314
|
ANDERSON, IAN
|
SANTA ROSA MEMORIAL HOSPITAL
|
|
Facilitating Positive Adaptation to Breast Cancer
|
5R01CA064710-11
|
$444,776
|
$44,478
|
ANTONI, MICHAEL
|
UNIVERSITY OF MIAMI CORAL GABLES
|
|
T cell alternative p38 activation pathway
|
Z01 BC 010774
|
$417,993
|
$104,498
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-09
|
$128,678
|
$12,868
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Southeast Cancer Control Consortium, Inc
|
3U10CA045808-21S1
|
$170,000
|
$1,700
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-21
|
$1,860,642
|
$18,606
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-33
|
$413,938
|
$41,394
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Studies of a novel BRCA1 tricomplex in breast cancer
|
5R01CA096805-05
|
$358,649
|
$35,865
|
AVRAHAM, HAVA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
SAN JUAN MB COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA052667-17
|
$484,826
|
$9,697
|
BAEZ, LUIS
|
SAN JUAN CITY HOSPITAL
|
|
Southwest Oncology Group
|
2U10CA027057-28
|
$255,214
|
$10,209
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Southwest Oncology Group
|
3U10CA027057-28S1
|
$43,000
|
$1,720
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Interim SWOG Committee Renewals (Breast, Head & Neck, Leukemia)
|
3U10CA032102-28S1
|
$187,055
|
$7,482
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE
|
3U10CA032102-28S2
|
$159,600
|
$6,384
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE
|
3U10CA032102-28S3
|
$316,222
|
$12,649
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE
|
5U10CA032102-28
|
$9,423,958
|
$376,958
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Subpopulations of Human Dendritic Cells
|
5R01CA078846-09
|
$292,811
|
$219,608
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
CD4+ Memory T-Cells in Human Lung Tumor Micorenvironment
|
5R01CA108970-03
|
$290,964
|
$218,223
|
BANKERT, RICHARD
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
|
Role of PKR in Growth Regulation
|
5R01CA086431-09
|
$323,212
|
$323,212
|
Barber, Glen
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Mechanisms of VSV-mediated Oncolysis
|
5R01CA095924-05
|
$287,658
|
$287,658
|
Barber, Glen
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Growth Control in Multiple Myeloma
|
5P01CA055819-13
|
$3,499,541
|
$349,954
|
BARLOGIE, BART
|
UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
|
|
Regional Oncology Research Center
|
3P30CA006973-45S1
|
$231,549
|
$2,315
|
BAYLIN, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-45S2
|
$126,362
|
$1,264
|
BAYLIN, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-45
|
$7,564,613
|
$75,646
|
BAYLIN, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
2U10CA035119-23
|
$1,740,827
|
$17,408
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group Clinical Trials
|
5U10CA017145-32
|
$456,370
|
$45,637
|
BENSON, AL
|
NORTHWESTERN UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S3
|
$137,869
|
$1,379
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S4
|
$232,326
|
$2,323
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S5
|
$250,000
|
$2,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-43
|
$11,526,509
|
$115,265
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Geisinger Clinical Oncology Program
|
5U10CA035448-24
|
$458,852
|
$9,177
|
BERNATH, ALBERT
|
GEISINGER MEDICAL CENTER
|
|
Antigen-specific T-cell activation, application to vaccines for Cancer and AIDS
|
Z01 SC 004020
|
$1,324,087
|
$132,409
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Natural Killer Cell Growth and Development
|
5R01CA041268-22
|
$337,399
|
$253,049
|
BIRON, CHRISTINE
|
BROWN UNIVERSITY
|
|
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML
|
2R01CA072669-11
|
$298,185
|
$98,401
|
Blazar, Bruce
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
SHPI Targeted Inhibition by Stibogluconate for Melanoma
|
5R01CA115494-02
|
$239,656
|
$239,656
|
BORDEN, ERNEST
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Expression and Function of Tob in T Lymphocytes
|
5R01CA104596-03
|
$316,479
|
$15,824
|
BOUSSIOTIS, VASSILIKI
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
SPORE in Pancreatic Cancer
|
5P20CA101955-05
|
$855,582
|
$171,116
|
BUCHSBAUM, DONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Southwest Oncology Group
|
2U10CA004919-48
|
$192,303
|
$7,692
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Southwest Oncology Group
|
3U10CA004919-48S1
|
$25,000
|
$1,000
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
The Ohio State University Comprehensive Cancer Center-Supplement
|
3P30CA016058-32S1
|
$232,765
|
$2,328
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-32S2
|
$84,897
|
$849
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
5P30CA016058-32
|
$3,716,537
|
$37,165
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
|
5R01CA100226-04
|
$262,798
|
$52,560
|
CAMPBELL, KERRY
|
INSTITUTE FOR CANCER RESEARCH
|
|
Therapy of Melanoma with Bortezomib and Interferon-alpha
|
3R21CA119588-02S1
|
$4,491
|
$4,491
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
Therapy of Melanoma with Bortezomib and Interferon-alpha
|
5R21CA119588-02
|
$257,668
|
$257,668
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
THERAPY OF CML
|
5P01CA049639-19
|
$3,552,240
|
$888,060
|
CHAMPLIN, RICHARD
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Novel Approaches to Stem Cell Transplantation
|
5P01CA047741-15
|
$1,686,422
|
$252,963
|
Chao, Nelson
|
DUKE UNIVERSITY
|
Total relevant funding to Interferon for this search: $34,907,923
|